Oesophageal adenocarcinoma (OAC) is a highly heterogeneous disease, dominated by large-scale genomic rearrangements and copy number alterations. Such characteristics have hampered conventional target-directed drug discovery and personalized medicine strategies contributing to poor outcomes for patients diagnosed with OAC. We describe the development and application of a phenotypicled OAC drug discovery platform incorporating image-based, high-content cell profiling and associated image-informatics tools to classify drug mechanism-of-action (MoA). We applied a high-content Cell Painting assay to profile the phenotypic response of 19,555 compounds across a panel of six OAC cell lines representing the genetic heterogeneity of disease, a pre-neoplastic Barrett's oesophagus line and a non-transformed squamous oesophageal line. We built an automated phenotypic screening and high-content image analysis pipeline to identify compounds that selectively modified the phenotype of OAC cell lines. We further trained a machinelearning model to predict the MoA of OAC selective compounds using phenotypic fingerprints from a library of reference compounds.
Introduction
Combined, the two major histological subtypes of oesophageal adenocarcinoma (OAC) and oesophageal squamous cell carcinoma (OSCC), represent the sixth leading cause of cancer deaths worldwide with less than one in five patients surviving five years from diagnosis 1 . A shift in epidemiology over the last 50 years has meant the incidence of OAC now vastly exceeds that of OSCC in western countries 2 , accounting for more than 80 % of oesophageal cancers in the United States 3 . Defining the optimal neoadjuvant treatment regime is an area of active investigation 4 as, current treatments all carry a significant risk of systemic toxicity, histological response rates remain poor 5 and only a limited subgroup of patients experience any survival benefit over surgery alone 6, 7 .
OAC is a highly heterogeneous disease, dominated by large scale genomic rearrangements and copy number alterations 8 . This has made clinically meaningful subgroups and well validated therapeutic targets difficult to define. Clinical trials with new molecular targeted agents have predominantly been directed towards epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) receptors [9] [10] [11] [12] but thus far have proven unsuccessful.
A potential explanation is the almost ubiquitous co-amplification of alternative receptor tyrosine kinases (RTKs) and downstream pathways leading to redundancy and drug resistance 8, 13, 14 . An alternative to target based drug discovery, and increasing in popularity with technological advances, is phenotypic drug discovery, defined as the identification of novel compounds or other types of therapeutic agents with no prior knowledge of the drug target. Recent advances in phenotypic screening include automated high-content profiling 15, 16 . This approach involves quantifying a large number of morphological features from cell or small-model organism assays in an unbiased way to identify changes and phenotypes of interest. One benefit to this method is that a target does not need to be predefined but the mechanism-of-action (MoA) of hit compounds can be inferred by reference to known compound sets using multivariate statistics and machine learning approaches. Thus, this may prove a beneficial strategy for complex, heterogeneous diseases were target biology is poorly understood and where modern-target directed drug discovery strategies have made little impact on patient care, as exemplified by OAC.
Taking an unbiased, profiling approach to phenotypic screening, we chose to apply the Cell Painting assay to capture large amounts of information on cellular and subcellular morphology to quantify cellular state across a panel of genetically distinct OAC cell lines. Cell Painting is an assay developed to capture as many biologically relevant morphological features in a single assay so as not to constrain discovery to what we think we already know 17, 18 . Therefore, upon chemical perturbation we can detect changes in a subset of profiled features allowing a phenotypic fingerprint to be assigned to a particular perturbation or compound 15, [19] [20] [21] . These fingerprints can then be used to identify specific phenotypic changes of interest, identify compounds that cause strong alterations in cell morphology suggesting changes in cellular state or stress, or predict MoA by similarity comparison to reference libraries of well annotated compound mechanisms 17, 21 
Materials and Methods
Cell Culture EPC2-hTERT cells were a kind donation from Anil Rustgis' Lab, University of Pennsylvania 22 .
Cell Line Authentication
Cell line identification (not carried out for the EPC2-hTERT line, as there is no reference sequence) was confirmed by short tandem repeat (STR) genotyping (Cell Line Authentication, Public Health England).
The cell-lines were confirmed to be mycoplasma negative using the Venor TM GeM Mycoplasma Detection PCR kit (MP0025; Sigma). Compound source plates were made at 1,000-fold assay concentration and added to the cells with an overall dilution in media of 1:1000 from source to assay plate.
Library concentrations ( Supplementary Table S1 ).
After 48 hours incubation in the presence of the compounds, cells were fixed by the addition of an equal volume of formaldehyde (8 %, 50 µL) (#28908, Thermo Scientific) to the existing media, incubated at room temperature (20 minutes) and
washed twice in PBS. Cells were then permeabilised in Triton-X100 (0.1%, 50 uL) and incubated at room temperature (20 minutes) followed by two more washes with PBS.
The staining solution ( Table 1 ) was prepared in bovine serum albumin solution (1 %). Staining solution was added to each well (25 µL) and incubated in the dark at room temperature (30 minutes), followed by three washes with PBS and no final aspiration. Plates were foil sealed.
Image Acquisition
Plates were imaged on an ImageXpress micro XLS (Molecular Devices, USA) equipped with a robotic plate loader (Scara4, PAA, UK). Four fields of view were captured per well using a 20x objective and five filters ( Table 1) .
Image Analysis
CellProfiler 2D image analysis CellProfiler v3.0.0 23 image analysis software was used to segment the cells and extract 733 features per cell per image. First the pipeline identified the nuclei from the DAPI channel and used these as seeds to aid a segmentation algorithm to identify the cell boundaries from the TxRed channel, and finally these two masks were subtracted to give the cytoplasm. These three masks marking the cellular boundaries were then used to measure morphological features including size, shape, texture, and intensity per object across the five image channels.
Image Preprocessing
The cell level data was aggregated to image level by taking the median for each 
Random Forest Classifier
The random forest classifier was implemented using R's Random Forest package with the following specified parameters; ntree = 500, data was stratified by class and the sample size was set to the smallest class size for balance. The images from three concentrations for each compound were pooled and treated as a single class. 
Results

Assay development
Since OAC is such a heterogeneous disease, we chose to develop a high-content Wheat Germ Agglutinin and switched to a different phalloidin supply ( Table 1) .
Machine learning
Standard assay quality control metrics such as Z'Factor are unsuitable for multiparametric assays, particularly cell based phenotypic profiling assays where a desired phenotype is unknown and/or there is a lack of positive controls [24] [25] [26] . In order to assess assay quality from a compound MoA profiling perspective we used
MoA prediction accuracy on a small well-annotated reference library of compounds with well-defined, known MoA ( Supplementary Table S2 ). For this, we trained a random forest classifier using the CellProfiler extracted phenotypic information from the images of cells treated with the reference set of compounds.
Accuracy in the ability to predict MoA was used to assess whether, the OAC and tissue matched control cell lines were amenable to the phenotypic profiling assay, further validate image segmentation was accurate, and ensure that the phenotypic information extracted was relevant and broad enough to allow accurate prediction of Here we wanted to confirm that they were equal to the rest of the panel and suitable for the assay pipeline. OAC-P4C is a particularly morphologically heterogeneous line so it was also important to ensure that image level data can be used for phenotypic compound profiling in these types of cell lines.
In order to visualise the phenotypic information extracted, we performed two data reduction methods; PCA and T-SNE, on the well level data for the small reference library of compounds and plotted the first two components, coloured by mechanistic class. These results demonstrate that distinct compound classes (e.g. HDAC inhibitors) generally cluster together, however some classes such as statins do not
produce strong phenotypes and clustering shows they are close to the DMSO controls, data for FLO-1 and MFD-1 cells are provided as exemplars. (Figure 2) .
We next optimised a random forest classifier to test MoA prediction on our reference library of well annotated compounds. The extracted features from three concentrations of each compound were pooled and used to train the classifier. We In order to confirm that the classifier was not overfitting we used leave-one-out cross-validation. We implemented leave-one-cell-line-out and trained it on five of the OAC lines, testing on the remaining line. Here, as expected it performed less well overall (Supplementary Fig. S1 ). However, there is still a very strong diagonal trend (Figure 3A, Supplementary Fig. S2 ).
Based on cell growth and survival (i.e nuclei count), we identified 27 compounds that were selectively active in two or more of our OAC lines. Here, hits were defined as having a z-score of -3 or more in the OAC lines and a difference of at least 2 in one or both of the control cell lines e.g. for a hit with a z-score of -3 in an OAC line, the zscore in the EPC-2 would have to be greater than or equal to 0. This comparison was made between each OAC line and the control lines to define hits and then selected if they were selectively active in at least two OAC lines across the panel ( Figure 3B) .
Compounds from the growth and survival analysis cluster into several therapeutic classes suggesting mechanistic pathways that may be selective for OAC cell growth and survival. Classes include antimetabolites and HDAC inhibitors. These classes were also identified in the morphometric phenotypic analysis (Supplementary Fig.   S2 ).
We performed hierarchical clustering of cell line responses to the compounds, as determined by the Mahalanobis metric (morphometric phenotypic analysis) and the z-scores (nuclei count) (Figure 3C and D) , enabling pharmacological discrimination of cell lines. These results show that the control cell lines; EPC2-hTERT and CP-A, can be discriminated from the OAC panel based on global drug screening data, providing confidence that our high-content cell painting assay can identify compounds with selectivity for OAC over the tissue matched control lines.
Antimetabolites are selectively lethal to OAC cells
From the subset of 3000 annotated compounds we identified the drug Methotrexate and three other structurally related antimetabolites; Pemetrexed, Raltitrexed and Aminopterin, as highly selective for OAC cell lines relative to tissue matched control CP-A and EPC2-hTERT cells in both the nuclei count and morphological phenotypic analyses. We therefore validated this class of compound for dose dependent activity.
Aminopterin was removed from further analysis due to its toxicity profile in the clinic 27 , however, it showed potent activity in an initial dose response in the OAC lines, validating it as a hit our screen (results not shown).
Nuclei count dose responses for Methotrexate, Pemetrexed and Raltitrexed demonstrated strong selectivity against the OAC lines, with IC50s ranging from 1-65 nM, and showed minimal cytotoxic or phenotypic activity in either the CP-A or the EPC2-hTERT line even at 10 µM (Figure 4A, Supplementary Table S3 ), validating our hit selection criteria.
Multiparametric phenotypic dose response profiles of the antimetabolites overlaid on the reference library of annotated compounds ( Supplementary Table S2 ) show strong dose dependent phenotypic changes, moving from phenotypically inactive (clustering with DMSO controls) to clustering with the DNA damaging agents at active concentrations (Figure 4B) in all but the JH-EsoAD1 and MFD-1 lines. All three compounds also showed little or no effect in the control lines EPC2-hTERT and CP-A, clustering closely with the DMSO controls at all concentrations tested.
Class probabilities from the pre-trained machine learning model for each of the compounds predicts them to belong to the DNA damage class for all but the MFD-1 and JH-EsoAD1 lines (Figure 4C) , consistent with the clustering above. Probabilities also increase in a dose dependent manner indicating cellular phenotypic activity follows a linear on-target dose response relationship. These results further confirm the ability of the Cell Painting assay to accurately predict MOA of validated hit compounds.
NanoString differential expression analysis revealed methotrexate treatment caused a significant reduction in the expression of Histone H3 subunits (HIST1H3B, HIST1H3G, HISTH3H) (Figure 4D ) in the sensitive cell lines only, with no effect in either of the tissue matched controls ( Supplementary Table S4 (Figure 5A) . Machine learning predicts it to be DNA damaging (91 % probability) in the OAC-P4C cells, however, its clustering is distinct and the machine learning probability that it is DNA damaging in the OE33 cell line is only 52 % (Figure 5B) . Therefore it may in fact represent a novel MoA or be acting to cause DNA damage in a novel way. This indicates that these compounds may be selectively targeting novel oesophageal cancer biology. Subsequent transcriptomic and proteomic pathway analysis and target deconvolution studies may reveal the mechanistic pathways involved.
Discussion
Conventional target-directed drug discovery strategies remain to make any impact on the discovery and translation of effective new treatments for oesophageal cancer patients. Key challenges in oesophageal cancer include a highly heterogeneous genetic landscape with few mutations in oncogenic drivers, thereby confounding the identification of clear drug-target hypothesis and modern personalized medicine strategies. In this study we sought to adapt and evaluate the utility of an advanced high-content phenotypic screening method as an empirical strategy for identifying novel drug targets, MoA and pharmacological classes which target OAC.
Here we have shown that combining high-content screening and image informatics with machine-learning can prove effective in the identification and mechanistic characterisation of hit compounds with selective activity upon OAC cell phenotypes.
The majority of multiparametric high-content screening assays and associated machine learning methods used to predict drug MoA are typically performed on a single cell line. In this study we have further shown that this format can be applied to heterogeneous panels of cancer cell lines and normal tissue match control cells for the identification and prioritization of hit compounds and MoA which demonstrate selectivity activity for OAC cells.
Machine-learning can be implemented as a tool for multiparametric phenotypic assay quality control (e.g. confirming if the assay is suitable as a discovery platform to classify specific cell phenotypes and elucidate MoA) as well as a tool for MoA deconvolution of hit compounds. Our results demonstrate that this can be standardised across heterogeneous panels of cells with reasonable accuracy. In addition, using bioinformatic approaches we hope that integration of phenotypic data with genetic data across our panel of diverse cell lines may provide insight into the selective activity of phenotypic hits and generate the basis for future genetic biomarker-based clinical trials in OAC.
Overall, our high-content OAC assay has proven effective in the identification and mechanistic characterisation of hit compounds, demonstrating its utility as a novel empirical strategy for the discovery of new therapeutic targets, chemical starting points and repurposing of existing drug classes to re-ignite drug discovery and development in OAC. See Table 1 for additional details about the stains and channels imaged. 
